Phase I Additional Study of Tolerance and Pharmacokinetics of Anlotinib in Patients With Advanced Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 28 Apr 2017
At a glance
- Drugs Anlotinib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 24 Apr 2017 Planned End Date changed from 1 Oct 2016 to 1 Apr 2017.
- 24 Apr 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Apr 2017.
- 24 Apr 2017 Status changed from recruiting to active, no longer recruiting.